[Federal Register: May 15, 2001 (Volume 66, Number 94)]
[Notices]
[Page 26871]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15my01-85]
[[Page 26871]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Glycoprotein Hormone
Superagonists
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in:
U.S. Patent Application Serial No. 09/185,408 filed May 6, 1996
entitled ``Glycoprotein Hormone Superagonists'', to N.V. Organon,
having a place of business in The Netherlands. The field of use may be
limited to the treatment of human infertility. The United States of
America is the assignee of the patent rights in this invention. This
announcement replaces two previous notices to grant an exclusive
license to this technology--64 FR 38685, July 19, 1999 and 65 FR 5878-
5879, February 7, 2000.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before July
16, 2001 will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Marlene Shinn, Technology Licensing Specialist,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:
(301) 496-7056, ext. 285; Facsimile: (301) 402-0220; e-mail:
MS482M@NIH.GOV.
SUPPLEMENTARY INFORMATION: This invention relates generally to modified
glycoprotein hormones and specifically to modifications to a human
glycoprotein, which create superagonist activity. Glycoprotein hormones
comprise a family of hormones, which are structurally related
heterodimers consisting of a species common sub-unit and a
distinct sub-unit that confers the biological activity for
each hormone.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 7, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 01-12124 Filed 5-14-01; 8:45 am]
BILLING CODE 4140-01-P